Ono Pharmaceutical (4528) · InitiativeFirst stated

Preparations for Adopting IFRS 18 in the Fiscal Year Ending March 2028

First written in FY2025. . Latest entry: FY2025.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Adoption of IFRS 18, Presentation and Disclosure in Financial StatementsA theme 42 companies write about · 0 as a headwind · 0 as a tailwind

23 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 42 companies compared. The sentences above are computed from all 42.

Full recordFilings, disclosures and news, newest first

FY2025First statedAnnual report
「IFRS 18 Presentation and Disclosure in Financial Statements　1 January 2027　Fiscal year ending March 2028　The impact of applying IFRS 18 on the Group’s consolidated financial statements is currently under consideration.」
It was stated for the first time that IFRS 18 is scheduled to be applied from the fiscal year ending March 2028 and that its impact on presentation and disclosure is under consideration.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.